Some Breast Cancer Tumors Can Stop Their Own Spread
News Aug 28, 2018 | Original story from the Garvan Institute of Medical Research
Cell culture of human breast cancer conditionally reprogrammed cells. Fluorescence red color represents MHC-I, and nuclei are shown in blue. Credit: Ewa Krawczyk. NCI/Georgetown Lombardi Comprehensive Cancer Center
The findings, uncovered in mice and patient tumors, are published in Nature Cell Biology. They reveal a previously unseen 'ecosystem' in advanced breast cancer, in which the primary breast tumor emits signals that halt the growth of secondary tumors elsewhere in the body.
The spread of cancer beyond the original tumor - known as metastasis - is the most deadly aspect of most cancers. Once a breast cancer has spread to other parts of the body, treatments are far less effective and a patient's prognosis worsens sharply. In Australia, 8 women die from breast cancer every single day1.
"This new research has yielded that rare thing," says Dr Christine Chaffer (Garvan), "- a clue from the cancer itself about new possibilities to fight its spread. Our goal is to work out how we can mimic this 'freezing' of secondary cancers, so that one day we might influence all breast cancers to keep their secondary tumors in check."
The researchers found that, in mice, primary breast tumors can influence 'breakaway cells' that have left the primary tumor to establish new tumors throughout the body. The primary tumor sends its message via the immune system, through an 'inflammatory response' provoked by the tumor. Immune cells spread through the body, locating the sites where breakaway cells have settled in preparation for the launch of new secondary tumors. Once the immune cells locate the breakaway cells, remarkably they are able to 'freeze' them - halting tumor growth.
"When these breakaway cells are settling, before they have established a new tumor, they are particularly vulnerable," explains Dr Chaffer, "because they are in an intermediate state, and their identity isn't very solid. It's at this point that the immune system can intervene."
"When breakaway cells are forced to remain in the transition state, they don't grow very well," remarks Dr Sandra McAllister (Brigham and Women's Hospital and Harvard Medical School, Boston), who co-led the research with Dr Chaffer, "and their ability to form a new tumor is severely compromised. So, remarkably, by activating the immune response, the primary tumor essentially shuts down its own spread."
Crucially, there is indirect evidence that the same process may also be happening in people. The team found that, in a group of 215 breast cancer patients at high risk for developing metastasis, patients with high levels of the same type of immune response had better overall survival compared to those with low levels.
Dr Chaffer and her lab are now devising how this discovery might be applicable in the clinic.
"When you have a primary tumor, there are untold numbers of breakaway cells that will travel throughout the body - but not all of them will form tumors," she says. "By some estimates less than 0.02% of breakaway cells will form secondary tumors 2-4- so we have a real opportunity to bring this number down to zero."
They have already discovered some of the signals the immune cells are sending to keep metastasis at bay. But they are casting a wide net, and looking at this process from many angles.
"We want to understand exactly what the tumor is releasing to activate this immune response, and how immune cells are targeting the secondary sites," concludes Dr Chaffer. "In principle, all of these steps present therapeutic opportunities that could be used to stop a cancer from developing any further."
The researchers hope to use the new information to find ways to suppress the spread of cancer in all breast tumors. In addition, they hope to apply their findings beyond breast cancer, to determine if similar processes may be exploited to suppress spread in other tumor types.
This article has been republished from materials provided by the Garvan Institute of Medical Research. Note: material may have been edited for length and content. For further information, please contact the cited source.
Mapping of a certain group of cells, known as oligodendrocytes, in the central nervous system of a mouse model of multiple sclerosis (MS), shows that they might have a significant role in the development of the disease. The discovery can lead to new therapies targeted at other areas than just the immune system.